IPO registrations (S-1, F-1) · Registrants
BRAINSTORM CELL THERAPEUTICS INC.
- SEC CIK
- 1137883 · filings on EDGAR ↗
- Former names
- BRAINSTORM CELL THERAPEUTICS INC (2004–2012); GOLDEN HAND RESOURCES INC (2003–2004); WIZBANG TECHNOLOGIES INC (2001–2003)
- Registration
- Form S-1, first filed 2001-05-24, last 2026-05-21; 5 initial registrations, 13 amendments
- Outcome
- Final prospectus filed 2012-07-19; declared effective 2012-07-13; withdrawal requested 2025-07-22
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 1325 AVENUE OF AMERICAS, 28TH FLOOR, New York, NY 10019
- EIN
- 20-7273918
- Ticker
- BCLI (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- BRAINSTORM CELL THERAPEUTICS INC. on the corporate pages
Offering terms
- Final price
- $0.29 per share (424B1 filed 2012-07-19)
- Shares sold
- 19,818,972
- Gross proceeds
- $5,747,502 before underwriting discounts and any over-allotment option
- Listing
- OTCQB under the symbol BCLI
- Lead underwriters
- Maxim Group
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: BRAINSTORM CELL THERAPEUTICS INC. Fuzzy (name and state)
- Form D issuer: BRAINSTORM CELL THERAPEUTICS INC. EXACT (CIK (EXACT))
- SEC filer: BRAINSTORM CELL THERAPEUTICS INC EXACT (CIK (EXACT))
- Person page: Jacob A Frenkel Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Malcolm S Taub Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2001-05-24 | S-1 | S-1 (registration) | WIZBANG TECHNOLOGIES INC | 0001015402-01-501410 ↗ |
| 2001-06-18 | S-1/A | S-1/A (amendment) | WIZBANG TECHNOLOGIES INC | 0001015402-01-501557 ↗ |
| 2001-07-25 | S-1/A | S-1/A (amendment) | WIZBANG TECHNOLOGIES INC | 0001015402-01-501922 ↗ |
| 2001-08-17 | S-1/A | S-1/A (amendment) | WIZBANG TECHNOLOGIES INC | 0001015402-01-502449 ↗ |
| 2003-03-03 | S-1/A | S-1/A (amendment) | WIZBANG TECHNOLOGIES INC | 0001022106-03-000016 ↗ |
| 2012-02-03 | S-1 | S-1 (registration) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-005706 ↗ |
| 2012-03-22 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-016623 ↗ |
| 2012-05-17 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-030249 ↗ |
| 2012-06-29 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-037444 ↗ |
| 2012-07-10 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-038881 ↗ |
| 2012-07-13 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC | 9999999995-12-002154 ↗ |
| 2012-07-19 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC | 0001144204-12-040129 ↗ |
| 2013-02-08 | S-1 | S-1 (registration) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-006961 ↗ |
| 2013-03-20 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-016474 ↗ |
| 2013-05-13 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-028350 ↗ |
| 2013-06-12 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-034520 ↗ |
| 2013-07-09 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-038773 ↗ |
| 2013-08-06 | S-1/A | S-1/A (amendment) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-043084 ↗ |
| 2013-08-12 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-13-002381 ↗ |
| 2013-08-13 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-13-045242 ↗ |
| 2014-07-10 | S-1 | S-1 (registration) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-14-042335 ↗ |
| 2014-07-24 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-14-044693 ↗ |
| 2014-07-24 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-14-002230 ↗ |
| 2015-02-10 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-15-007447 ↗ |
| 2015-02-10 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-15-007452 ↗ |
| 2015-02-10 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-15-000368 ↗ |
| 2015-02-10 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-15-000369 ↗ |
| 2015-05-01 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-15-001141 ↗ |
| 2015-05-27 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-15-001456 ↗ |
| 2015-06-10 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-15-001597 ↗ |
| 2016-11-21 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-16-006279 ↗ |
| 2018-06-29 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-18-001675 ↗ |
| 2018-09-28 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-18-051595 ↗ |
| 2018-09-28 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-18-002494 ↗ |
| 2019-08-30 | 424B1 | 424B1 (final prospectus) | BRAINSTORM CELL THERAPEUTICS INC. | 0001144204-19-043045 ↗ |
| 2019-08-30 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-19-002000 ↗ |
| 2021-08-19 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-21-003250 ↗ |
| 2024-09-06 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-24-002744 ↗ |
| 2024-09-27 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-24-002998 ↗ |
| 2025-07-22 | RW | RW (withdrawal request) | BRAINSTORM CELL THERAPEUTICS INC. | 0001104659-25-069626 ↗ |
| 2026-05-21 | S-1 | S-1 (registration) | BRAINSTORM CELL THERAPEUTICS INC. | 0001104659-26-064628 ↗ |
| 2026-06-02 | EFFECT | EFFECT (declared effective) | BRAINSTORM CELL THERAPEUTICS INC. | 9999999995-26-001853 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2012-07-10 | S-1/A | registration statement | $0.18 | 30,000,000 | $5,298,000 | OTCQB BCLI | 1 | primary document; price line, shares sentence, proceeds computed, cover names 1 | document ↗ | |
| 2012-07-19 | 424B1 | final prospectus | $0.29 | 19,818,972 | $5,747,502 | OTCQB BCLI | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| STOLICK DAVID | Officer | Chief Financial Officer | 6 | 2006–2010 | |
| ARBEL IRIT | Director | 26 | 2006–2026 | ||
| Drucker Yoram | Officer | Chief Operating Officer | 2 | 2006–2007 | |
| GREENFIELD MICHAEL D | Director; Other | 5 | 2006–2007 | ||
| SHORR ROBERT G L | Director | 18 | 2006–2017 | ||
| Lebovits Chaim | Officer | Chief Executive Officer; President; President & CEO; President & Co-CEO; See Remarks | 29 | 2007–2026 | |
| Lion Moshe | Director | 3 | 2007–2010 | ||
| ACCBT Corp. | TenPercentOwner | 7 | 2007–2011 | ||
| Javitt Jonathan C | Director | 7 | 2007–2010 | ||
| RAMOT AT TEL AVIV UNIVERSITY LTD | TenPercentOwner | 1 | 2007 | ||
| TEL AVIV UNIVERSITY ECONOMIC CORP LTD | TenPercentOwner | 1 | 2007 | ||
| TEL AVIV UNIVERSITY | TenPercentOwner | 1 | 2007 | ||
| Efrati Abraham | Officer | Chief Executive Officer | 3 | 2007–2009 | |
| TAUB MALCOLM S | Director | 28 | 2009–2021 | person page Fuzzy | |
| Israeli Avi | Director | 7 | 2010–2014 | ||
| Sossover Liat | Officer | Chief Financial Officer | 5 | 2010–2014 | |
| Pinkas Alon | Director | 7 | 2011–2016 | ||
| Harel Adrian | Officer | Acting Chief Executive Officer; Chief Executive Officer; Chief Operating Officer | 5 | 2011–2012 | |
| Friedman Mordechai | Director | 8 | 2011–2016 | ||
| ACC International Holdings Ltd. | Other | 12 | 2011–2020 | ||
| Schor Chen | Director | 7 | 2011–2018 | ||
| Natanson Alon | Officer | Chief Executive Officer | 1 | 2013 | |
| Yablonka Uri | Director; Director,Officer | Chief Operating Officer; EVP and Chief Business Officer; EVP & Chief Business Officer | 16 | 2014–2026 | |
| Fiorino Anthony S. | Officer | Chief Executive Officer | 5 | 2014 | |
| Patlis Alla | Officer | See Remarks | 6 | 2015–2026 | |
| Bibring Yoram | Officer | Chief Financial Officer | 5 | 2015 | |
| Almenoff June Sherie | Director | 7 | 2017–2021 | ||
| Araya Arturo | Director; Director,Officer; Officer | Chief Commercial Officer | 6 | 2017–2019 | |
| Kern Ralph Dr. | Officer | COO and Chief Medical Officer | 11 | 2017–2022 | |
| Rubin Eyal | Officer | CFO and Treasurer | 2 | 2017 | |
| Polverino Anthony J. | Director | 10 | 2018–2026 | ||
| Shah Preetam | Officer | EVP, CFO and Treasurer | 4 | 2019–2020 | |
| Abbhi Sankesh | Director | 4 | 2020–2021 | ||
| FRENKEL JACOB A | Director | 7 | 2020–2026 | person page Fuzzy | |
| Setboun David | Officer | EVP and COO | 3 | 2020 | |
| Lindborg Stacy | Director; Officer | Co-Chief Executive Officer; EVP, Head Global Clin Research | 10 | 2020–2026 | |
| Waclawski Anthony | Officer | See Remarks | 2 | 2020 | |
| Bairu Menghisteab | Director | 3 | 2021–2026 | ||
| Taylor Kirk | Officer | Chief Medical Officer | 2 | 2023 | |
| Naor Nir | Director | 4 | 2023–2026 | ||
| Dagher Ibrahim B. | Director; Officer | Chief Medical Officer | 5 | 2024–2026 | |
| HARTOUNIAN HARTOUN | Director; Officer | EVP, Chief Operating Officer | 4 | 2024–2026 | |
| Pitts Peter Joe | Director; Director,Officer | Executive Chairman | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-08-09 | BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Indefinite | $0 | 3 | 1 |
| 2018-06-20 | BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Indefinite | $0 | 6 | 1 |
| 2015-01-21 | BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | Indefinite | $0 | 8 | 1 |
| 2014-07-01 | BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | $10,500,000 | $10,500,000 | 11 | 1 |
| 2014-05-09 | BRAINSTORM CELL THERAPEUTICS INC. | Biotechnology | $2,470,590 | $1,632,689 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | BRAINSTORM CELL THERAPEUTICS INC. | NY | State business registries | name and state |
| Form D issuer | BRAINSTORM CELL THERAPEUTICS INC. | NY | Form D private offerings | CIK (EXACT) |
| Nonprofit | PINES MODERN CORPORATION | NY | Nonprofits (IRS Form 990) | same street address and ZIP code, 1325 AVE OF AMERICAS 28TH FL 10019 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | BRAINSTORM CELL THERAPEUTICS INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Brainstorm Cell Therapeutics Inc. | NY | Trademarks (USPTO) | name and state |
| Person page | Jacob A Frenkel | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Malcolm S Taub | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NY first:
- Acorda Therapeutics, Inc. NY
- ANAVEX LIFE SCIENCES CORP. NY
- CytRx Oncology Corp NY
- Omrix Biopharmaceuticals, Inc. NY
- Protara Therapeutics, Inc. NY
- COGNITION THERAPEUTICS INC NY
- Bavarian Nordic A/S / ADR NY
- Qrons Inc. NY
- Prevail Therapeutics Inc. NY
- MeiraGTx Holdings plc NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health